The role of heparin in reducing in-hospital complications and three-month mortality rates in hospitalized COVID-19 patients.

Calabretta, F; Preti, P S; Russo, M; Klersy, C; Di Sabatino, A

Calabretta, F; Preti, P S; Russo, M; Klersy, C; Di Sabatino, A.

Afiliação

Calabretta F; Department of Internal Medicine, IRCCS Policlinico San Matteo Foundation, University of Pavia, Pavia, Italy. Electronic address: p.preti@smatteo.pv.it.
Preti PS; Department of Internal Medicine, IRCCS Policlinico San Matteo Foundation, University of Pavia, Pavia, Italy.
Russo M; Department of Internal Medicine, IRCCS Policlinico San Matteo Foundation, University of Pavia, Pavia, Italy.
Klersy C; Clinical Epidemiology and Biometry Service. IRCCS Policlinico San Matteo Foundation. Pavia, Italy.
Di Sabatino A; Department of Internal Medicine, IRCCS Policlinico San Matteo Foundation, University of Pavia, Pavia, Italy.

Eur J Intern Med ; 101: 124-127, 2022 07.

Article em En | MEDLINE | ID: mdl-35307245

Assuntos

COVID-19; Heparina; Anticoagulantes/uso terapêutico; Enoxaparina; Heparina/uso terapêutico; Hospitais; Humanos

Palavras-chave

Covid-19; Enoxaparin; Myocardial infarction; Venous thrombosis

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Heparina / COVID-19 Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Heparina / COVID-19 Idioma: En Ano de publicação: 2022 Tipo de documento: Article